Stockpolly
Search
ACRV · NASDAQ · Biotechnology

Acrivon Therapeutics (ACRV)

Develops cancer therapies and companion diagnostics around drug-specific proteomic patient selection.

$2.15
Pre-market−0.00 (−0.23%)
At close$2.16(+4.11%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000−100
Gross profit000000000100
162117212525212220212019
Research & development101511151918151614151514
666666666555
General & administrative606660666555
Other expenses000000000100
Operating income−16−21−18−21−25−25−22−23−20−20−20−19
221332221111
Interest income201332222111
Interest expense020000000000
Other non-operating income−2−2−1−3−3−2−2−2−15−1−1
Income before tax−14−19−16−19−22−23−20−21−18−19−19−18
Net income from continuing operations−14−19−16−19−22−23−20−21−18−19−19−18
Net income−14−19−16−19−22−23−20−21−18−19−19−18
EPS, basic−$0.66−$0.86−$0.73−$0.52−$0.59−$0.60−$0.51−$0.55−$0.47−$0.49−$0.49−$0.43
EPS, diluted−$0.66−$0.86−$0.73−$0.52−$0.59−$0.60−$0.51−$0.55−$0.47−$0.49−$0.49−$0.43
Weighted average shares, basic222223363838383839393942
Weighted average shares, diluted222223363838383839393942
EBITDA−14−19−16−19−22−23−19−21−18−25−19−18
Depreciation & amortization000000000000
EBIT−14−19−16−19−22−23−20−21−18−25−19−18